SPARC

Which are the latest news on SPARC?

Why is Sun Pharma Advanced Research Company Ltd falling/rising?

As of 05-Sep, Sun Pharma Advanced Research Company Ltd's stock is declining, currently at 199.50, down 1.48%. The stock has underperformed its sector and the broader market, with decreasing investor participation and negative momentum indicators despite strong long-term growth potential.

As of 05-Sep, Sun Pharma Advanced Research Company Ltd's stock price is falling, currently at 199.50, reflecting a decrease of 3.0 points or 1.48%. This decline is notable as the stock has underperformed its sector by 0.91% today and has experienced a trend reversal after two consecutive days of gains. <BR><BR>The stock's performance over the past week shows a decline of 3.83%, which is significantly worse than the Sensex's drop of 0.97%. Additionally, the stock has fallen 3.79% over the past month, while the Sensex has decreased by 2.44%. This trend indicates a consistent underperformance relative to the broader market.<BR><BR>Investor participation has also decreased, with delivery volume on September 3 falling by 38.13% compared to the five-day average. This drop in trading activity may reflect waning interest among investors, contributing to the stock's price decline. Furthermore, while the stock is trading above its 5-day and 200-day moving averages, it is below its 20-day, 50-day, and 100-day moving averages, suggesting a weakening momentum.<BR><BR>Despite these negative indicators, the company has shown strong long-term growth potential, with net sales growing at an annual rate of 428.32% and operating profit at 144.13%. However, the recent price movements and declining investor participation indicate that the stock is currently facing downward pressure.

Who are in the management team of SPARC?

The management team of SPARC includes T Rajamannar, Sudhir V Valia, Bhavna Doshi, Ferzaan Engineer, Robert Spiegel, and Dilip S Shanghvi as Chairman (Non-Executive).

The management team of SPARC includes the following individuals:<BR><BR>1. T Rajamannar - Director<BR>2. Sudhir V Valia - Director<BR>3. Bhavna Doshi - Independent Director<BR>4. Ferzaan Engineer - Independent Director<BR>5. Robert Spiegel - Independent Director<BR>6. Dilip S Shanghvi - Chairman (Non-Executive)<BR><BR>If you need more information about their roles or contributions, feel free to ask!

What does SPARC do?

Sun Pharma Advanced Research Company Limited (SPARC) is a clinical stage bio-pharmaceutical firm focused on developing new drugs and delivery systems. As of June 2026, it reported net sales of 40 Cr and a net loss of 21 Cr, with a market cap of INR 6,426 Cr.

Overview: <BR>Sun Pharma Advanced Research Company Limited (SPARC) is a clinical stage bio-pharmaceutical company engaged in creating new drugs and delivery systems within the Pharmaceuticals & Biotechnology industry, categorized as a Small Cap.<BR><BR>History: <BR>SPARC was incorporated on March 22, 2006. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 40 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: -21 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 6,426 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 4.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.42 <BR>Return on Equity: 116.94% <BR>Price to Book: 5.03 <BR><BR>Contact Details: <BR>Address: Sun Pharma Advanced Res Centre, Akota Road Akota Vadodara Gujarat : 390020 <BR>Tel: 91-265-2330815/2339257 <BR>Email: secretarial@sparcmail.com <BR>Website: http://www.sparc.life

Who are the peers of the SPARC?

Peers of SPARC include P & G Health Ltd, Strides Pharma, Aarti Pharma, Sanofi India, Senores Pharma, Bliss GVS Pharma, Supriya Lifesci, Innova Captab, IOL Chemicals, and FDC. SPARC shows excellent growth and average management risk, with a 1-year return of 42.53%, lower than Bliss GVS Pharma's 295.64% but higher than Sanofi India's -39.16%.

Peers: The peers of SPARC are P & G Health Ltd, Strides Pharma, Aarti Pharma, Sanofi India, Senores Pharma, Bliss GVS Pharma, Supriya Lifesci, Innova Captab, IOL Chemicals, and FDC.<BR><BR>Quality Snapshot: Excellent management risk is observed at P & G Health Ltd and Sanofi India, while Average management risk is found at Strides Pharma, Aarti Pharma, Senores Pharma, Bliss GVS Pharma, SPARC, IOL Chemicals, and FDC, and Good management risk is noted at Supriya Lifesci and Innova Captab. Growth is Excellent at SPARC and Senores Pharma, Good at Strides Pharma and Innova Captab, while Below Average growth is seen at P & G Health Ltd, Aarti Pharma, Sanofi India, Bliss GVS Pharma, Supriya Lifesci, IOL Chemicals, and FDC, and Average growth is noted at Senores Pharma. Capital Structure is Excellent at P & G Health Ltd, Aarti Pharma, Sanofi India, Bliss GVS Pharma, Supriya Lifesci, Innova Captab, and IOL Chemicals, Average at SPARC, and Below Average at Strides Pharma and FDC.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Bliss GVS Pharma at 295.64%, while the lowest is Sanofi India at -39.16%. SPARC's 1-year return of 42.53% is significantly higher than Sanofi India's but lower than Bliss GVS Pharma's. Additionally, the six-month return is negative for Sanofi India and FDC.

How big is SPARC?

As of 31st August, Sun Pharma Advanced Research Company Ltd has a market capitalization of 6,426.00 Cr, classifying it as a Small Cap company, with recent net sales of 1,909.45 Cr and net profit of 1,584.29 Cr over the last four quarters.

As of 31st August, <BR><BR>Market Cap: Sun Pharma Advanced Research Company Ltd has a market capitalization of 6,426.00 Cr, classifying it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 1,909.45 Cr, while the sum of Net Profit for the same period is 1,584.29 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2026. Shareholder's Funds stand at 1,338.83 Cr, and Total Assets amount to 2,168.61 Cr.

Should I buy, sell or hold Sun Pharma Advanced Research Company Ltd?

When is the next results date for Sun Pharma Advanced Research Company Ltd?

The next results date for Sun Pharma Advanced Research Company Ltd is 10 August 2026.

The next results date for Sun Pharma Advanced Research Company Ltd is scheduled for 10 August 2026.

Are Sun Pharma Advanced Research Company Ltd latest results good or bad?

Sun Pharma Advanced Research Company Ltd's latest results show a significant net profit driven by a one-time gain, but the underlying operational performance remains weak, with persistent losses and a negative net worth, indicating ongoing challenges for the company.

The latest results for Sun Pharma Advanced Research Company Ltd (SPARC) present a mixed picture. In Q4 FY26, the company reported a significant net profit of ₹1,761.34 crores, which is a remarkable increase compared to the previous quarter. However, this figure is largely driven by a one-time gain, which has raised concerns about the sustainability of this performance.<BR><BR>Net sales also saw an extraordinary increase of 21,831.60% quarter-on-quarter, reaching ₹1,853.22 crores. This surge is primarily attributed to a one-time transaction, likely related to licensing or asset divestment, rather than a reflection of ongoing operational success. In contrast, the company had been experiencing consistent losses in prior quarters, with net losses ranging from ₹51.87 crores to ₹107.33 crores.<BR><BR>While the operating margin and PAT margin showed dramatic improvements, these metrics are inflated due to the exceptional nature of the recent gains. The underlying operational performance remains concerning, as the company has a negative net worth of ₹216.95 crores and has been burning through cash, with operating cash flow remaining deeply negative.<BR><BR>In summary, while the latest results may appear strong on the surface due to the one-time gain, they do not indicate a sustainable turnaround for the company. The persistent operational losses and negative net worth suggest that SPARC is still facing significant challenges ahead.

Is SPARC technically bullish or bearish?

As of November 27, 2025, the trend is mildly bearish due to daily moving averages and weekly Bollinger Bands indicating bearish sentiment, despite mixed signals from the MACD and KST, suggesting a cautious approach.

As of 27 November 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish sentiment and the weekly Bollinger Bands also showing a mildly bearish outlook. The MACD on the weekly is mildly bullish, but the monthly remains bearish, creating a mixed signal. The KST aligns with the weekly MACD, being mildly bullish, while the OBV is mildly bearish on the weekly timeframe. Overall, the lack of strong bullish signals and the presence of bearish indicators suggest a cautious approach.

How has been the historical performance of SPARC?

SPARC has experienced a significant decline in financial performance over the past three years, with net sales dropping from 238.78 crore in March 2023 to 71.77 crore in March 2025, and operating losses worsening from -203.18 crore to -321.35 crore in the same period. Overall, the company's financial metrics indicate ongoing operational challenges.

Answer:<BR>The historical performance of SPARC shows a significant decline in key financial metrics over the past three years, particularly in net sales, operating profit, and net profit.<BR><BR>Breakdown:<BR>SPARC's net sales decreased from 238.78 crore in March 2023 to 75.55 crore in March 2024, and further down to 71.77 crore in March 2025. The total operating income followed a similar trend, dropping from 238.78 crore in March 2023 to 71.77 crore in March 2025. The company faced substantial operating losses, with operating profit (PBDIT) worsening from -203.18 crore in March 2023 to -321.35 crore in March 2025. Profit before tax also reflected this negative trend, moving from -222.58 crore in March 2023 to -342.78 crore in March 2025. Consequently, profit after tax showed a similar decline, falling from -222.58 crore in March 2023 to -342.51 crore in March 2025. The company's total liabilities decreased from 830.13 crore in March 2023 to 333.22 crore in March 2025, while total assets also fell from 830.13 crore to 333.22 crore in the same period. Cash flow from operating activities remained negative, with a cash outflow of -360 crore in March 2025 compared to -429 crore in March 2024. Overall, SPARC's financial performance has deteriorated significantly over the years, indicating ongoing challenges in its operations.

How has been the historical performance of SPARC?

SPARC has faced significant financial challenges over the past three years, with net sales declining from 238.78 Cr in March 2023 to 71.77 Cr in March 2025, and increasing losses reflected in negative operating profit and profit after tax. Despite some cost control efforts, the company has seen a substantial decrease in total assets and liabilities, alongside persistent negative cash flow from operating activities.

Answer:<BR>The historical performance of SPARC shows significant challenges over the past three years, particularly in terms of revenue and profitability.<BR><BR>Breakdown:<BR>SPARC's net sales have declined sharply from 238.78 Cr in March 2023 to 75.55 Cr in March 2024, and further to 71.77 Cr in March 2025. Total operating income followed a similar trend, decreasing from 238.78 Cr in March 2023 to 71.77 Cr in March 2025. The company's total expenditure, excluding depreciation, decreased from 452.84 Cr in March 2023 to 394.91 Cr in March 2025, indicating some cost control efforts. However, operating profit (PBDIT) remained negative, worsening from -203.18 Cr in March 2023 to -321.35 Cr in March 2025. The profit before tax also showed a negative trend, moving from -222.58 Cr in March 2023 to -342.78 Cr in March 2025. Consequently, the profit after tax reflected similar losses, with figures of -222.58 Cr, -387.21 Cr, and -342.51 Cr for the respective years. The company's total liabilities decreased from 830.13 Cr in March 2023 to 333.22 Cr in March 2025, while total assets also fell from 830.13 Cr to 333.22 Cr in the same period. Cash flow from operating activities remained negative, with -360.00 Cr in March 2025, although cash flow from investing activities turned positive at 157.00 Cr. Overall, SPARC's financial performance indicates a trend of declining sales and increasing losses, alongside a significant reduction in total assets and liabilities.

Who are the top shareholders of the SPARC?

The top shareholders of SPARC include Shanghvi Finance Private Ltd with 42.28%, followed by individual investors at 18.99%, and the Sun Pharmaceutical Industries Key Employees Benefit Trust at 3.18%. Mutual funds and foreign institutional investors hold 1.01% and 1.45%, respectively, with no pledged promoter holdings.

The top shareholders of SPARC include the promoters, with Shanghvi Finance Private Ltd holding the largest stake at 42.28%. There are no pledged promoter holdings. In addition, mutual funds hold a total of 1.01% through 10 schemes, while foreign institutional investors (FIIs) account for 1.45% through 31 different FIIs. The highest public shareholder is the Sun Pharmaceutical Industries Key Employees Benefit Trust, which holds 3.18%. Individual investors collectively own 18.99% of the company.

Has SPARC declared dividend?

No Dividend History Available